U.S. Markets closed
  • S&P 500

    4,255.15
    +7.71 (+0.18%)
     
  • Dow 30

    34,393.75
    -85.85 (-0.25%)
     
  • Nasdaq

    14,174.14
    +104.72 (+0.74%)
     
  • Russell 2000

    2,326.15
    -9.66 (-0.41%)
     
  • Crude Oil

    71.09
    +0.21 (+0.30%)
     
  • Gold

    1,868.80
    +2.90 (+0.16%)
     
  • Silver

    28.02
    -0.02 (-0.07%)
     
  • EUR/USD

    1.2133
    +0.0026 (+0.2184%)
     
  • 10-Yr Bond

    1.5010
    +0.0390 (+2.67%)
     
  • Vix

    16.39
    +0.74 (+4.73%)
     
  • GBP/USD

    1.4100
    -0.0017 (-0.1198%)
     
  • USD/JPY

    110.0500
    +0.4150 (+0.3785%)
     
  • BTC-USD

    40,227.49
    +1,340.68 (+3.45%)
     
  • CMC Crypto 200

    1,002.43
    +33.59 (+3.47%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Celyad Oncology SA (NASDAQ: CYAD) has announced initial clinical data from the Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in patients with relapsed or refractory multiple myeloma.

  • The data will be presented at the upcoming European Hematology Association (EHA) Virtual Congress 2021.

  • No severe/life-threatening treatment-related adverse events nor evidence of Graft-versus-Host disease were reported from the completed first dose-level (DL1) cohort of the trial.

  • Initial results at a low dose of 30x106 cells per infusion showed preliminary signs of clinical activity, including a confirmed partial response.

  • CYAD-211 is an investigational, non-gene edited allogeneic CAR T candidate engineered to co-express a single hairpin RNA (shRNA) and a BCMA-targeting chimeric antigen receptor.

  • Price Action: CYAD shares are trading 21.9% higher at $6.47 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.